BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Daiichi Sankyo
Baxter
QuintilesIMS
Moodys
Cantor Fitzgerald
Johnson and Johnson
US Department of Justice
Boehringer Ingelheim

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,756,033

« Back to Dashboard

Which drugs does patent 6,756,033 protect, and when does it expire?

Patent 6,756,033 protects TYVASO and is included in one NDA.

This patent has thirteen patent family members in eleven countries.
Summary for Patent: 6,756,033
Title: Method for delivering benzindene prostaglandins by inhalation
Abstract:A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
Inventor(s): Cloutier; Gilles (Chapel Hill, NC), Crow; James (Chapel Hill, NC), Wade; Michael (Chapel Hill, NC), Parker; Richard E. (Spring Hill, TN), Loyd; James E. (Nashville, TN)
Assignee: United Therapeutics Corporation (Washington, DC)
Application Number:10/212,149
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Composition;

Drugs Protected by US Patent 6,756,033

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
United Therap TYVASO treprostinil SOLUTION;INHALATION 022387-001 Jul 30, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF PULMONARY HYPERTENSION BY INHALATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,756,033

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,521,212 Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,756,033

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2011201907 ➤ Subscribe
Japan 4819224 ➤ Subscribe
Japan 2002539154 ➤ Subscribe
Spain 2203449 ➤ Subscribe
European Patent Office 1354588 ➤ Subscribe
European Patent Office 1161234 ➤ Subscribe
Denmark 1161234 ➤ Subscribe
Germany 60004181 ➤ Subscribe
China 1379665 ➤ Subscribe
China 1196479 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
Johnson and Johnson
Chinese Patent Office
Novartis
Cipla
Colorcon
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot